CareFusion Expands Specialty Disposables Business with Acquisition from GE Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CareFusion Expands Specialty Disposables Business with Acquisition from GE Healthcare


CareFusion has signed a definitive agreement to acquire the Vital Signs division of GE Healthcare for $500 million, CareFusion announced in a press release. Vital Signs manufactures single-patient-use consumables for respiratory care and anesthesiology. The acquisition will expand CareFusion's Specialty Disposables business by adding global scale and new products for anesthesiology.

CareFusion expects the acquisition to advance its goal of expanding in international markets. The acquisition will accelerate the transformation of the Specialty Disposables business from a distributor to a vertically integrated manufacturer. With the addition of the Vital Signs portfolio, CareFusion will become a full-line provider of more than 20,000 single-use consumables for respiratory care and anesthesiology, including circuits for oxygen and anesthesia, humidification, masks, filters, pressure infusers, and temperature-management products.

The acquisition is expected to be completed for the Vital Signs business in the United States, China and certain other countries by Dec. 31, 2013. The company expects to finalize the remainder of the transaction during its third quarter, ending March 31, 2014, subject to regulatory review and customary closing conditions. Headquartered in Totowa, New Jersey, Vital Signs has more than 1000 employees in three primary locations worldwide, including manufacturing operations in Shenzhen, China, and a global, field-based sales organization.

Source: CareFusion


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here